S-Diclofenac

S-Diclofenac (ACS 15) is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac activates the p53 signaling pathway, and inhibits the activation of JNK. S-Diclofenac exhibits antioxidant and anti-inflammatory activities[1][2][3][4].

Product Specifications

CAS Number

[912758-00-0]

Product Name Alternative

ACS 15; ATB-337

UNSPSC

12352005

Target

JNK; MDM-2/p53; SOD

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/s-diclofenac.html

Purity

99.20

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1)OC3=CC=C(C(SS4)=CC4=S)C=C3

Molecular Formula

C23H15Cl2NO2S3

Molecular Weight

504.47

References & Citations

[1]Wallace JL, et al. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology. 2007 Jan;132 (1) :261-71.|[2]Sidhapuriwala J, et al., Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat. Eur J Pharmacol. 2007 Aug 13;569 (1-2) :149-54.|[3]Zhang H, et al., S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. PLoS One. 2011;6 (10) :e26441|[4]Baskar R, et al., Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur J Pharmacol. 2008 Oct 10;594 (1-3) :1-8.